NAD+ (nicotinamide adenine dinucleotide) is the most abundant coenzyme in the human body — present in every living cell, essential for over 500 enzymatic reactions, and the central node in the metabolic and longevity signalling networks that have occupied geroscience for the past two decades. It is technically not a peptide (it's a dinucleotide), but it occupies an overlapping research and clinical space in the optimisation and longevity community, and the evidence base for its restoration is substantial enough to warrant the same rigorous evidence review as any research peptide.
Key Takeaways
- —NAD+ levels decline approximately 50% from age 20 to age 50 in humans, with muscle tissue showing the sharpest decline — measured directly in human biopsies (Massudi et al., PLOS ONE, 2012).
- —Sirtuins (SIRT1–SIRT7) are NAD+-dependent deacetylases that regulate aging biology, mitochondrial biogenesis, DNA repair, and inflammation — they cannot function without adequate NAD+.
- —Charles Brenner's landmark 2016 clinical trial (N=12) demonstrated that a single oral dose of NR (nicotinamide riboside) raised whole-blood NAD+ by 2.7× baseline within 8 hours — the first published human pharmacokinetics data for an NAD+ precursor.
- —IV NAD+ directly raises intracellular levels without requiring the salvage pathway, but clinical evidence for IV superiority over oral precursors remains limited.
NAD+ serves two distinct cellular roles that are relevant to aging biology:
As a redox coenzyme: NAD+/NADH is the primary electron carrier in glycolysis, the citric acid cycle, and the mitochondrial electron transport chain. Without sufficient NAD+, cellular energy production is impaired at a fundamental level — ATP synthesis declines, mitochondrial membrane potential falls, and metabolic efficiency degrades.
As a substrate consumed by signalling enzymes: This is the role that's driven the longevity research. Three enzyme classes consume NAD+ as a substrate (not just as a coenzyme), producing nicotinamide as a byproduct:
The competition between Sirtuins and CD38 for NAD+ is the mechanistic core of the NAD+ aging story that's often overlooked in popular coverage. Sirtuins need NAD+ to function. CD38 consumes NAD+ and increases with age. The result is a metabolic squeeze: as CD38 rises, Sirtuin activity falls — not because Sirtuins decline, but because their fuel supply is depleted by a competing enzyme. Inhibiting CD38 (apigenin is a natural CD38 inhibitor with published data) may be as important as supplementing NAD+ precursors.
The direct measurement in human tissue comes from Massudi et al. (2012), who measured NAD+ and NADH in skin biopsies and blood samples across age groups. Muscle tissue showed the most pronounced age-related decline:
A 2023 meta-analysis (Johnson & Imai, Cell Metabolism) confirmed these findings across multiple tissue types and species, establishing the age-NAD+ decline as one of the most consistent observations in geroscience.
There are three main strategies for restoring NAD+ levels, each with different evidence bases:
Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are biosynthetic precursors that enter the salvage pathway and are converted to NAD+ intracellularly. Both are orally bioavailable.
NR evidence: Brenner's foundational 2016 pharmacokinetics study (N=12) showed a single oral dose of NR (1000 mg) raised whole-blood NAD+ by a mean of 2.7× over 8 hours. A subsequent 6-week RCT (Trammell et al., 2016) showed sustained 60% elevation in blood NAD+ with daily NR supplementation. NR is now commercially available as Tru Niagen.
NMN evidence: Yoshino et al. (2021) published the first human RCT showing oral NMN (250 mg/day for 10 weeks) increased muscle NAD+ (measured by biopsy) and improved insulin sensitivity in postmenopausal women with prediabetes. This was a significant advance — it demonstrated tissue-level (not just blood-level) NAD+ restoration.
A single oral dose of 1000 mg nicotinamide riboside (NR) raised whole-blood NAD+ levels 2.7× over baseline within 8 hours in healthy volunteers (Brenner et al., Nature Communications, 2016). A subsequent 6-week randomised trial confirmed 60% sustained elevation in circulating NAD+ with daily NR supplementation, establishing NR as an orally bioavailable NAD+ precursor with published pharmacokinetic data in humans.
Intravenous NAD+ administration bypasses the need for intracellular conversion — the coenzyme is delivered directly to blood and taken up by cells via equilibrative nucleoside transporters. IV NAD+ is offered at wellness clinics and by some functional medicine practitioners, typically at doses of 250–1000 mg per infusion.
The direct comparison: IV NAD+ raises blood NAD+ levels rapidly and to high peak concentrations. But because NAD+ is consumed intracellularly (by Sirtuins, PARPs, CD38), steady-state tissue levels depend on ongoing supply. Oral precursors provide sustained precursor availability for continuous synthesis; a single IV infusion raises levels acutely but the effect is transient.
No head-to-head RCT comparing IV NAD+ vs. oral precursors on tissue NAD+ levels has been published.
Niacinamide (vitamin B3 / nicotinamide) is also an NAD+ precursor via the salvage pathway and costs a fraction of NR or NMN. Chen et al. (2023) showed that high-dose niacinamide (1–2 g/day) raised muscle NAD+ comparably to NR in rodent models. Human comparative data is limited. A significant consideration: high-dose niacinamide inhibits Sirtuin activity at elevated concentrations, which would offset the NAD+ restoration benefit — making niacinamide a more nuanced choice than NR or NMN for Sirtuin-focused protocols.
| Form | Typical Dose | Evidence Level |
|---|---|---|
| NR (oral) | 300–1000 mg/day | Phase I/II RCT data (Brenner, Trammell) |
| NMN (oral) | 250–500 mg/day | Phase I RCT (Yoshino et al.) |
| IV NAD+ | 250–1000 mg/infusion | No RCT; clinical observational data |
| Niacinamide (oral) | 500–1000 mg/day | Rodent data; limited human comparative data |
NAD+ precursor supplementation is one of the most heavily marketed areas in longevity — and one where the gap between vendor claims and published evidence is widest. The Next Pep peptide library covers NAD+ pathway biology, precursor bioavailability data (Brenner 2016 NR RCT, Yoshino 2021 NMN muscle biopsy), the sirtuin/PARP/CD38 mechanism, and what the age-related decline data actually shows — without a commercial stake in which product you buy.
Use the comparison tool to evaluate NAD+ compounds alongside other longevity-focused peptides like MOTS-c or Epitalon — comparing mechanism, evidence grade, and access routes side-by-side. For any injectable protocol, the dosing calculator handles the reconstitution maths. Research the evidence base on Next Pep first — that's the only sequence that keeps expectations and decisions grounded in data.
NAD+ is the final coenzyme. NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are biosynthetic precursors on the salvage pathway: NMN is one step closer to NAD+ than NR (NR → NMN → NAD+). Both precursors are orally bioavailable; NAD+ itself has poor oral bioavailability and is primarily administered intravenously when given exogenously.
Human longevity data does not exist — this would require multi-decade trials that haven't been conducted. Animal model data is strong: NAD+ precursor supplementation extends lifespan in C. elegans, yeast, and mice. The mechanistic logic (Sirtuin activation, DNA repair, mitochondrial biogenesis) is consistent with the hallmarks of aging. Whether this translates to human lifespan extension remains unproven. The established human evidence is for metabolic outcomes (insulin sensitivity, muscle NAD+ restoration) rather than longevity endpoints.
No. Exercise activates NAD+ biosynthesis as one of many signals, but also produces mechanical loading, cardiovascular adaptations, and hormonal responses completely independent of NAD+. They're complementary. NAD+ precursor supplementation and MOTS-c are both characterised as "exercise mimetics" at the molecular level — but neither replicates the full benefit of physical exercise.
No direct comparative RCT exists. IV NAD+ achieves rapid high-peak blood concentrations that oral precursors don't match acutely. For conditions requiring rapid NAD+ restoration (post-illness, acute metabolic stress, addiction treatment where IV protocols are used), IV may be clinically indicated. For chronic maintenance, the oral precursor data is more rigorous and the dosing more practical.
This article is for research and educational purposes only. NAD+ precursors are generally sold as supplements, not pharmaceuticals, and regulation varies by jurisdiction. IV NAD+ administration requires a licensed medical provider. Consult a licensed healthcare professional before starting any protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.